Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the use of albumin combined with endovascular treatment in patients who have an acute ischemic stroke in the anterior circulation. This trial is a prospective, multicenter, open-label, randomized controlled study aiming to determine the safety and effectiveness of adding albumin to the standard endovascular therapy for this condition. Patients will be selected based on specific criteria including stroke severity and imaging findings. Participants will be randomly assigned to one of two groups one receiving albumin along with endovascular treatment, and the other receiving only the recommended endovascular treatment. Albumin is given as a 25% human albumin intravenous infusion at a dose of 0.5gkg maximum 37.5g once initially and then daily for the next three days. Both groups will also receive acute stroke care and secondary prevention therapies according to current guidelines. During the study, participants will undergo initial imaging tests such as CT or MRI scans to confirm stroke location and exclude hemorrhage, along with laboratory tests and stroke severity assessments including the NIH Stroke Scale and modified Rankin Scale. Vital signs will be monitored, and patients will be followed for 90 days after randomization via telephone to evaluate their recovery and quality of life. The primary outcome is the proportion of patients achieving good functional status or returning to their baseline by 90 days.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of starting direct oral anticoagulants DOACs early versus later in patients who have acute ischemic stroke caused by atrial fibrillation and who develop bleeding complications after emergency endovascular treatment. This multicenter, prospective, open-label, randomized controlled trial aims to determine the best timing to initiate DOAC therapy to balance stroke recurrence and bleeding risks. Participants are assigned to one of two groups one begins any DOAC within 4 weeks after stroke onset early initiation, and the other starts DOACs between 4 and 8 weeks after stroke onset delayed initiation. The trial compares these two timing strategies following emergency endovascular therapy to see which approach is safer and more effective. During the study, participants will be monitored for outcomes including recurrent ischemic stroke, symptomatic brain bleeding, and death over 90 days. Additional assessments include quality of life, functional recovery, vascular events, and bleeding complications up to one year. Researchers will track hospital stay length and use clinical scales such as the modified Rankin Scale and EQ-5D-5L questionnaire to evaluate recovery and health status. The total study duration spans the treatment and follow-up periods up to one year.